Ampio Pharmaceuticals, Inc.

280 articles with Ampio Pharmaceuticals, Inc.

• Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino

  11/23/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), today announced it will host a conference call with its CEO and Chairman, Michael Martino, who will provide a corporate and business on Wednesday, December 1, 2021, at 4:30 pm EDT/ 2:30 pm MT.

• Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave

  11/22/2021

  Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, announced that Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediately.

• Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Ampio Pharmaceuticals, Inc. today reported results for the three- and nine-month periods ended September 30, 2021 and provided a corporate overview and business update.

• Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update

  10/28/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT.

• Ampio Pharmaceuticals Strengthens Management Team and Board of Directors

  10/13/2021

  -- Holli Cherevka promoted to President and Chief Operating Officer -- Howard Levy joins as Chief Medical Officer -- J. Kevin Buchi and Michael A. Martino join Board of Directors -- Mike Macaluso, CEO of Ampio, realigns his responsibilities with the Ampio executive team and Board while undergoing medical treatment

• Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

  9/21/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) in the Phase II AP-019 clinical trial in India

• Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)

  9/15/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee (OAK).

• Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action

  8/13/2021

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today announced a preprint version of a manuscript, "LMWF5A Demonstrates an Anti-Inflammatory Mode of Action and Similar Drug Targets to Dexamethasone in Activated PBMC," has been posted on In Review, a preprint platform hosted on Research Square.

• Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting

  8/12/2021

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company's proxy statement in advance of its upcoming annual meeting.

• Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

  8/11/2021

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will host one-on-one investor meetings at the following investor conferences:

• Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting

  7/29/2021

  Ampio Pharmaceuticals announced details on the Company's poster presentation, "Efficient Applied Toxicology during COVID-19: A Preclinical Study that Advanced Clinical Use of Ampion," being given virtually at the American College of Toxicology 42nd Annual Meeting, November 14 to 17, 2021, at the Gaylord National Harbor in Washington, DC.

• Ampio Pharmaceuticals to Present at Aspen Lung Conference

  7/27/2021

  Ampio Pharmaceuticals announced details on the Company's poster presentation, "Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option," being given at the 63rd annual Thomas L. Petty Aspen Lung Conference, September 20 to 23, 2021, at the Gant Conference Center in Aspen, Colorado.

• Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update

  7/14/2021

   Ampio Pharmaceuticals today announced it will host a conference call to discuss financial results for the quarter ended June 30, 2021 , and provide a corporate business update on Wednesday, August 4, 2021, at 4:30 pm EDT/ 2:30 pm MT.

• Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

  6/25/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced randomization and dosing of patients in its multi-center AP-019 Phase II clinical trial, using inhaled Ampion™

• Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index

  6/18/2021

  Ampio Pharmaceuticals announced that the Company is expected to join the small cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of this year's reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 28, 2021, accordingly to a preliminary list of additions posted on June 4, 2021.

• Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK

  6/17/2021

  Ampio Pharmaceuticals today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing Ampion for treating osteoarthritis of the knee (OAK).

• Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

  6/15/2021

  Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India.

• 

  COVID-19 News: Ocugen Secures Manufacturing, Ampio Stops Study and More

  6/15/2021

  Please check out the biopharma industry's COVID-19 stories that are trending for June 15, 2021.

• Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo

  6/14/2021

  Ampio Pharmaceuticals announced details on the Company's poster presentation, "Pivoting From One to Multiple Production Platforms to Treat COVID," being given at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo in Boston, Massachusetts from November 1st to 3rd, 2021.

• Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium

  6/11/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), today announced that management will participate in a series of one-on-one meetings with institutional investors throughout the day at the Alliance Global Partners' Virtual Summer Healthcare Symposium